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Abstract
Background: There are no commercially available vaccines against human protozoan parasitic diseases, despite the
success of vaccination-induced long-term protection against infectious diseases. East Coast fever, caused by the
protist Theileria parva, kills one million cattle each year in sub-Saharan Africa, and contributes significantly to hunger
and poverty in the region. A highly effective, live, multi-isolate vaccine against T. parva exists, but its component
isolates have not been characterized. Here we sequence and compare the three component T. parva stocks within
this vaccine, the Muguga Cocktail, namely Muguga, Kiambu5 and Serengeti-transformed, aiming to identify
genomic features that contribute to vaccine efficacy.
Results: We find that Serengeti-transformed, originally isolated from the wildlife carrier, the African Cape buffalo,
is remarkably and unexpectedly similar to the Muguga isolate. The 420 detectable non-synonymous SNPs were
distributed among only 53 genes, primarily subtelomeric antigens and antigenic families. The Kiambu5 isolate is
considerably more divergent, with close to 40,000 SNPs relative to Muguga, including >8,500 non-synonymous
mutations distributed among >1,700 (42.5 %) of the predicted genes. These genetic markers of the component
stocks can be used to characterize the composition of new batches of the Muguga Cocktail.
Conclusions: Differences among these three isolates, while extensive, represent only a small proportion of the
genetic variation in the entire species. Given the efficacy of the Muguga Cocktail in inducing long-lasting protection
against infections in the field, our results suggest that whole-organism vaccines against parasitic diseases can be
highly efficacious despite considerable genome-wide differences relative to the isolates against which they protect.
Keywords: Theileria parva, East coast fever, Live vaccine, Muguga Cocktail, Protozoan parasite, Genome sequence,
Single nucleotide polymorphisms, Comparative genomics, Vaccinology
* Correspondence: jcsilva@som.umaryland.edu
4Institute for Genome Sciences, University of Maryland School of Medicine,
Baltimore, USA
8Department of Microbiology and Immunology, University of Maryland
School of Medicine, Baltimore, USA
Full list of author information is available at the end of the article
© 2015 Norling et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Norling et al. BMC Genomics  (2015) 16:729 
DOI 10.1186/s12864-015-1910-9
Background
Theileria parva is an intracellular tick-transmitted proto-
zoan parasite native to eastern, central, and southern
Africa, and the causative agent of East Coast fever (ECF)
in cattle. The vectors are ticks within the genus Rhipice-
phalus, mainly R. appendiculatus, and the primary mam-
malian host is the African Cape buffalo (Syncerus caffer).
While the African buffalo is an asymptomatic carrier of
T. parva, cattle are evolutionarily recent hosts and typic-
ally succumb rapidly to the disease [1]. The parasite,
which is transmitted as a sporozoite during tick feeding,
invades lymphocytes of buffalo and cattle. In infected
lymphocytes, the parasite divides in synchrony with the
host cells while inducing uncontrolled proliferation and
‘immortalization’ of the host cells. Later in the course of
the infection, T. parva undergoes merogony resulting in
lysis of transformed host cells, and finally the differenti-
ation into the piroplasm stage. Development of the piro-
plasm stage occurs in red blood cells, which are ingested
during tick feeding, completing the developmental cycle.
Within the tick, the parasite undergoes sexual reproduction
in the gut and differentiates through several stages ultim-
ately resulting in the generation of sporozoites in the tick
salivary gland, following meiosis (reviewed in [2]). Clinically,
ECF is characterized by fever, generalized disease of the
lymph nodes and a reduction in the number of white blood
cells. Susceptible Bos taurus animals usually die within
three to four weeks as a result of widespread lympho-
cytolysis in the lymphoid tissues and pulmonary oedema
associated with invasion of the lung lymph node tissue by
parasitized lymphocytes [1].
A method of immunization has been established to
control development of clinical ECF in cattle, based on
inoculation with a preparation of live Theileria sporozo-
ites extracted from ground-up, infected whole ticks [3].
A potentially fatal dose of sporozoites is inoculated sub-
cutaneously to initiate an infection, which is then controlled
by concomitant injection of a long-acting formulation of
oxytetracycline. This approach is known as “Infection and
Treatment Method” or ITM (reviewed in [4, 5]). Long-
lasting, heterologous protection is obtained with this
immunization method using the “Muguga Cocktail”, a for-
mulation containing three stocks of T. parva – Muguga,
Kiambu5, and Serengeti-transformed [4]. In the absence
of further challenge, the ECF immunity induced by
ITM vaccination lasts for at least 43 months [6], but
since febrile reactions to challenge increase with time
since last exposure it is believed that, with regular nat-
ural exposure to the parasite, this immunity may be
maintained over a longer period of time [6].
Deployment of this vaccine has occurred primarily in
the Tanzanian Maasai pastoralist sector, with approxi-
mately one million calves vaccinated to date, but it has
also been used on a smaller scale in pilot projects in the
dairy sector in Uganda and elsewhere in East Africa. The
success of vaccination in Tanzania has stimulated re-
gional demand for ITM including in Southern Sudan
and Kenya [7]. One of the major drawbacks of ITM is
that, if carried out incorrectly, the immunization proced-
ure can lead to severe ECF-like symptoms. This problem
has recently been considerably reduced by using higher
doses of oxytetracycline [5].
Challenges associated with scaling up delivery of ITM
are the use of live parasites, requiring a secured liquid
nitrogen supply and an uninterrupted cold chain for de-
livery to the farmer, and the high production cost of the
three independent stocks that are combined to produce
the T. parva Muguga Cocktail. A further issue is that
production of each new vaccine batch requires infection
of cattle followed by application of ticks, during which
genetic recombination may occur, and finally the com-
bination of material from ground ticks, each carrying a
variable amount of one of the three vaccine stocks [8].
Therefore, the composition of each batch of immuniz-
ing stabilate is likely to differ, leading to a requirement
for molecular characterization of component stocks, as
part of quality control. Lastly, as perhaps most signifi-
cant of all, is the fact that upon ITM vaccination cattle
do not clear the parasite, but instead become carriers
with low-level parasitemia. Therefore, when Muguga
Cocktail-based ITM vaccination is first introduced into
new geographic regions, the risk of it failing to induce
cross-protection against the locally circulating T.
parva population, and the introduction of novel T.
parva genotypes from the vaccine preparation into
these parasite populations [9], necessitates close moni-
toring of vaccinated cattle. The remarkable success of
ITM in field settings, together with the challenges
highlighted above, have led to a renewed interest in
identifying the molecular basis of this vaccine’s broad
efficacy. In addition to improving ITM, this knowledge
could also be applied to leverage development of an ef-
ficacious subunit vaccine that avoids the drawbacks of
live immunization.
The advent of next generation sequencing has made
determination of complete genome sequences of T.
parva cost-effective [8]. In this study, we have sequenced
the genome of the T. parva Muguga Cocktail vaccine
component stocks Kiambu5 and Serengeti-transformed.
We have also re-sequenced a clonal parasite, Muguga
clone 2 (hereafter Muguga2), derived from the T. parva
Muguga stock, which represents the third component of
the Muguga Cocktail [8]. Comparison of these genomes
aims to provide insight into antigen gene variant combi-
nations that render this vaccine cocktail particularly ef-
fective in the field, as well as providing baseline data on
the component stocks. Additionally, the data generated
can be used to develop single nucleotide polymorphism
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panels for high resolution monitoring of vaccine com-
position and of breakthrough infections.
Results
Whole genome sequencing data
The three isolates included in this study were se-
quenced on two different sequencing platforms, result-
ing in data with different read lengths and depth of
coverage (Additional file 1: Table S1). For Serengeti-
transformed and Muguga2, that were sequenced using
454 technology, 98.8 % and 98.1 % of the reads ob-
tained aligned to the reference T. parva Muguga
genome, respectively. For Serengeti-transformed, the
mean read length was 541 bp, and the median was
549 bp, and for Muguga2, the mean was 470 bp and
median was 480 bp. The total number of mapped bases
corresponds to a theoretical sequence coverage of 58X
for Serengeti-transformed and 29X for Muguga2.
The whole genome sequence data for the Kiambu5
stock was generated using Ion Torrent technology.
Eighty three percent of all sequencing wells were used.
Quality control resulted in the elimination of 30 % of
reads, which were either primer dimers, or of low quality
as determined by standard Ion Torrent filters. A total
of > 3.6 million reads passed quality control checks, and
these exhibited a mean length of 225 bp, and a median
length of 209 bp. Of these, 94 % mapped to the reference
T. parva Muguga sequence, resulting in theoretical
sequence coverage of 39X for the Kiambu5 genome.
DNA sequence polymorphism and genetic relationship
among the components of the T. parva Muguga Cocktail
The level of genome sequence similarity between these
three T. parva stocks included in the Muguga Cocktail,
namely Muguga, Serengeti-transformed, and Kiambu5, is
high but variable, as determined by SNP densities that
vary between 0.10 SNPs/Kb for Serengeti-transformed to
4.70 SNPs/Kb for Kiambu5 relative to Muguga (Table 1).
These SNP densities are likely an underestimation, since
SNPs can only be identified in the regions of the reference
genome to which sequence reads from the query isolate
map. In fact, there was incomplete genome coverage from
all isolates, with 0.55 %, 0.29 % and 5.61 % of the Muguga
genome lacking read coverage from Muguga2, Serengeti-
transformed and Kiambu5, respectively (Fig. 1).
Sequencing of Muguga2, a second clone derived from the
Muguga stock, that is different from the clone used to gen-
erate the T. parva reference genome, is included primarily
as a reference for internal variation within the stock. The
results confirm that Muguga2 is nearly identical to the ref-
erence genome, with only 586 variants identified across the
whole genome (Table 1). The Kiambu5 isolate is the most
distinct of the three, with 39,296 SNPs relative to the T.
parva Muguga reference. The majority of sequence variants
between the Kiambu5 and the reference Muguga isolate, a
subset of 27,732 SNPs, are shared with the KiambuZ464
clone that was sequenced previously by Hayashida and col-
laborators [10]. Unexpectedly, Serengeti-transformed ap-
pears to be remarkably similar to the Muguga reference,
with only 957 sequence variants identified between the two
isolates, 416 of which are shared with Muguga2 (Fig. 1).
The SNPs found in each isolate were classified into syn-
onymous, non-synonymous, intronic or intergenic based
on the updated annotation of the reference genome assem-
bly of the T. parva Muguga isolate (see Methods for details
on re-annotation).
Despite the fact that these stocks were not cloned prior
to cattle infection, no biallelic SNPs were detected in
Serengeti-transformed, and only 18 of the 39,296 SNPs
were scored as biallelic in Kiambu5, well within the error
rate of Ion Torrent sequencing technology [11]. This result
suggests that, in both isolates, only a single clone was de-
tectable at the piroplasma stage of infection.
We used the isolates sequenced in this study, as well as
other cattle and buffalo strains previously sequenced by
Hayashida et al. [10], to determine the relationship among
the three constituents of the Muguga Cocktail in the con-
text of the genomic information available for T. parva
(Fig. 2). Our analysis shows the Kiambu5 stock clusters
with the previously sequenced Kiambu clone, KiambuZ464,
as would be expected. However, the Serengeti-transformed
stock did not cluster with other buffalo-derived strains, and
instead appears to be extremely similar to the Muguga ref-
erence strain. This indicates that the Serengeti-transformed
stock currently used in the Muguga Cocktail vaccine most
likely is not the original buffalo-derived stock.
Whole genome differences between Serengeti-transformed
and Muguga
The high similarity between these two isolates allows the
detailed scrutiny of the mutations most likely to be of
Table 1 Number of SNPs identified between each T. parva stock in the Muguga Cocktail and the reference Muguga strain
Isolate Total number
of SNPs
Synonymous Non-synonymous Nonsense Indels Intron Number of genes
with non-syn SNPs
Serengeti-transformed 957 291 420 1 0 121 53
Kiambu5 39,296 20,086 8,587 16 748 7,615 1,708
Muguga2 586 206 264 1 0 48 52
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phenotypic relevance. Sequence reads from the Serengeti-
transformed isolate mapped with 100 % coverage to 4063
of 4084 protein-coding genes in the reference T. parva
Muguga isolate, a reflection of the negligible nucleotide se-
quence divergence between the two isolates. Of the 21
genes with incomplete read coverage, ten have less than
90 % sequence coverage. All these 21 genes are members of
multigene families, including Tpr (Theileria parva repeat),
sub-telomeric variable secreted protein (SVSP)-like and
SfiI-like genes, and the lack of read mapping is likely the re-
sult of mapping ambiguity. Of the 957 variants between
Serengeti-transformed and Muguga, 291 are synonymous,
420 are non-synonymous, and one is a nonsense mutation.
From this set of variants, 416 are shared between the
Serengeti-transformed and Muguga2 stocks, including
the nonsense mutation. This nonsense mutation is in
the 4th amino acid in the protein encoded by TpMugu-
ga_03g00616 (TP03_0616 in the original annotation;
see Methods for details regarding new nomenclature),
a locus that is part of the hyper-variable Tpr region, in
chromosome 3 of T. parva Muguga. The Tpr locus
consists of a series of tandemly arrayed, rapidly evolv-
ing genes [12–14] and in T. parva Muguga has five
predicted transmembrane domains, suggesting that the
protein encoded is membrane-associated. The presence
of the nonsense mutation implies that not all proteins
encoded in the Tpr locus are functional in all strains of
T. parva. Alternatively, one of several downstream in-
a b
Fig. 1 Single Nucleotide Polymorphisms (SNP) in each of the Muguga Cocktail component T. parva stocks relative to the reference T. parva
Muguga isolate. a) Number of base pairs in the reference T. parva Muguga genome assembly with no read coverage from each of the three
isolates. SNPs cannot be identified in this fraction of the genome, respectively 0.55 % (45,837 bp), 0.29 % (24,439 bp) and 5.61 % (466,092 bp)
of the genome, in the comparisons with Muguga clone 2, Serengeti-transformed and Kiambu5. b) Identified SNPs unique to, and shared among,
Muguga clone 2, Kiambu5, and Serengeti-transformed isolates
Fig. 2 Phylogenetic relationships of twelve T. parva isolates. Genomic distances are measured in SNPs detected within the coding region of 200
randomly selected genes. Support was obtained from 500 bootstrap replicates. Represented isolates include T. parva stocks analyzed in this study, and
the additional stocks described by Hayashida et al. in [10], namely the cattle-derived T. parva parasite stocks "Entebbe", "Katumba", "Nyakizu", "ChitongoZ2",
"KateteB2", "KiambuZ464", and "MandaliZ22", as well as the African Cape buffalo-derived stocks "Lawrencei", and "Z5E5". Stocks are labeled according to
country of origin: northern end of the distribution -Kenya, Uganda and Rwanda (dark green); north-central region –Tanzania (teal); central region –Zambia
(blue). The three vaccine isolates are shown (bold-italics font)
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frame methionine-encoding codons might function as
the true start codon.
In total, 61 protein-coding sequences (CDSs) have
changes relative to Muguga, with 53 having non-
synonymous variants (Additional file 2: Table S2). These
CDSs are clustered in a few specific genomic locations, in
particular close to the telomeres (Fig. 3). A total of 14 genes
encode proteins with well-characterized function, 13 of
which contain non-synonymous SNPs (Table 2).
Notably, seven of these genes with non-synonymous
SNPs encode ABC-transporters, including the previously
characterized TpABC2 (TpMuguga_03g00864) [15], with
the remaining six comprising three translation initiation
factor IF-2 genes, an F-box-like/WD repeat-containing
protein TBL1XR1, a DNA replication factor CDT1-
like, and a papain family cysteine protease. The 61 vari-
ant genes were evaluated for the presence of trans-
membrane and GPI-anchored motifs and for predicted
product localization. While no GPI-anchored peptides
were identified, all the eight ABC-transporters had 11-
13 trans-membrane domains, while the three transla-
tion initiation factor IF-2 genes and the papain family
cysteine protease all have a single putative trans-
membrane domain.
The ABC transporter gene family is characteristically
located in the genomic region that separates sub-
telomeric repeats families from the core of the chromo-
somes where most single copy genes are located [13].
The polymorphic TpABC2 locus and its homologs
were evaluated further to determine the location of the
variant residues. The trans-membrane regions showed
non-synonymous SNP densities from 0.0 – 1.50 %,
while non-synonymous SNP densities for intra- and
extra-cellular regions were generally 0.0-1.68 %, and
0.0-1.60 % respectively. Notably though, TpMu-
guga_04_00021 had a non-synonymous SNP density of
7.3 % in its predicted intracellular regions.
Papain cysteine proteases are of particular interest in
apicomplexan vaccinology. In T. parva they are thought
to facilitate lymphocyte invasion [16]. Papain family cyst-
eine proteases have been considered as potential vaccine
targets in the related apicomplexan Plasmodium falcip-
arum [17], and the previously described T. parva anti-
gen Tp8, in chromosome 2 (TpMuguga_02g00140), is a
papain family cysteine protease. The polymorphic papain
cysteine protease identified here (TpMuguga_03g00280)
is located in chromosome 3, and its antigenic potential
warrants further investigation.
Fig. 3 Distribution of variants in the Serengeti-transformed and Kiambu5 isolates relative to the genome of the T. parva Muguga reference isolate. For each
of the four T. parva Muguga chromosomes the location of the protein coding genes in shown (purple), with genes encoded in the forward and reverse
strands in the top and bottom central tracks, respectively. Genes with non-synonymous differences between Serengeti and Muguga are shown in red.
Known antigens are shown in green. Variants were estimated in 2Kb-long, non-overlapping windows; for each of the isolates, the proportion of
the window with read coverage (orange; min-max = 0-100 % coverage) is displayed, as is the number of SNPs per window (blue; min-max = 0-32 SNPs/Kb)
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Table 2 Loci encoding well-characterized peptide products, which contain SNPs between the Serengeti-transformed stock and reference Muguga strain. Variants were also
found in 47 hypothetical proteins (Additional file 2: Table S2)
Locus Tag /2005 Locus Tag IDa Product Name TM
Domainsb
Protein Localization
/ Confidencec
Serengeti-transformed SNPsd Kiambu5 SNPse
Syn Nsyn Syn Nsyn
TP01_0011 TpMuguga_01g00011f ABC transporter 11 _ / 2 9 11 ≥66f ≥14f
TP02_0016 TpMuguga_02g00016f ABC transporter 13 _ / 2 2 2 ≥21f ≥7f
TP02_0017 TpMuguga_02g00017f ABC transporter 12 _ / 3 19 17 ≥11f ≥8f
TP02_0940 TpMuguga_02g00940f ABC transporter 12 _ / 1 1 ≥0f ≥0f
TP02_0951 TpMuguga_02g00951f ABC transporter 11 _ / 1 44 37 ≥9f ≥2f
TP03_0007 TpMuguga_03g00007f ABC transporter 11 _ / 1 7 4 ≥11f ≥9f
TP03_0864 TpMuguga_03g00864 ABC transporter 13 _ / 2 5 3 10 6
TP04_0021 TpMuguga_04g00021f ABC transporter 13 _ / 1 10 24 ≥43f ≥23f
TP02_0449 TpMuguga_02g00449 DNA replication factor CDT1 like 0 _ / 2 4 1
TP02_0448 TpMuguga_02g00448 F-box-like/WD repeat-containing protein TBL1XR1 0 _ / 1 1 1
TP03_0280 TpMuguga_03g00280 Papain family cysteine protease 1 _ / 2 12 7 1 1
TP04_0278 TpMuguga_04g00278 Translation initiation factor IF-2 1 S / 2 4 8 5
TP04_0279 TpMuguga_04g00279 Translation initiation factor IF-2 1 S / 2 1 3
TP04_0280 TpMuguga_04g00280f Translation initiation factor IF-2 1 S / 1 1 3 ≥2f ≥2f
aLocus Tag Identifiers according to the updated whole genome gene structural re-annotation
bNumber of transmembrane domains
cProtein localization predictions based on TargetP: C = chloroplast; M =mitochondrion; S = Secretory pathway; _ = Any other location. Prediction confidence: 1 =max; 5 =min
dSNPs between the Serengeti-transformed isolate and the reference Muguga isolate. Both synonymous (Syn) and non-synonymous (Nsyn) SNP counts are shown
eSNPs between Kiambu5 and the reference Muguga isolate
fThis genes coding sequence(s) had at least one position with <10x mapping coverage in the Kiambu5 stock, and thus there is likely more variation in the actual sequence
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Finally, the translation initiation and replication factors,
as well as the F-box-like protein, are all involved in tran-
scription regulation. Their presence among this small set of
highly variable proteins is unexpected but not entirely sur-
prising, since one of the previously identified antigens, Tp5,
is a eukaryotic initiation factor EIF-1A.
Parasite multigene families, often encoded in subtelo-
meric regions, play a fundamental role in pathogenesis
of eukaryotic parasites, most notably in evasion of the
host immune system, and as such they tend to be quite
variable [18–21]. In T. annulata, the Tash1/SuAT1 fam-
ily proteins have a potential role in host cell transform-
ation and possibly in host cell immortalization [22] and
there are homologues of these genes in T. parva that
have not yet been tested functionally. The SVSP family
is a subtelomeric gene family with a highly complex ex-
pression pattern [23]. Therefore, it is not surprising that
many of the 47 genes with nucleotide differences be-
tween Muguga and Serengeti-transformed, which do not
encode a well-characterized protein, belong to multigene
families (Additional file 2: Table S2). Of these, 17 are
members of the hyper variable Tpr (Theileria parva re-
peat) region. All these genes have between 1 and 11
transmembrane regions, and some contain putative
domains. In addition, nine genes show high similarity
(either full length or partial) to the Theileria annulata
SfiI family. The SfiI family is a sub-telomeric gene fam-
ily characterized by the presence of an SfiI restriction
site. Twelve of the 47 uncharacterized proteins have
strong sequence similarity to the T. parva sub-
telomeric variable secreted protein (SVSP) family, in-
cluding two full length proteins as well as ten with
similarity only over a terminal end of the protein, in-
cluding four of the SfiI family proteins mentioned
above, as well with six other hypothetical proteins. Fi-
nally, one gene had a predicted zinc finger and BTB
domain-containing at the amino terminus, one was
very similar to a T. annulata cysteine repeat modular
protein 2, one to the T. annulata Tash1 gene, one to
Babesia bigemina Vam6/Vps39-like gene, and finally
eight genes had no non-hypothetical BLASTx hits, al-
though some contained conserved domains.
Whole genome sequence diversity between Kiambu5 and
Muguga
A total of 39,296 variants were identified between Kiambu5
and the reference T. parva Muguga isolate, affecting the
coding region of 2,233 CDSs. Of these variants, 8,587 are
non-synonymous mutations, which fall in 1,708 protein-
coding genes (Table 1, Additional file 3: Table S3). Two pat-
terns are markedly different from what was determined in
the Serengeti-transformed vs. Muguga comparison. First,
instead of primarily restricted to subtelomeric regions, the
non-synonymous mutations are distributed throughout the
genome (Fig. 3). Secondly, for a large number of genes in
the T. parva Muguga reference genome, coverage with
reads sequenced from the Kiambu5 genome is either partial
(804) or absent (16), a result of the considerable sequence
divergence observed between the two isolates.
Among all sequence variants found, 13 SNPs are exclu-
sively shared with Serengeti-transformed, 25 with both
Serengeti-transformed and Muguga2, and no SNPs are
shared between Kiambu5 and Muguga2 to the exclusion of
Serengeti-transformed (Fig. 1). Of the 13 SNPs shared
between Kiambu5 and Serengeti-transformed, five are
intergenic, four are located in TpMuguga_04g00278, two
in TpMuguga_01g02945, and one each in TpMugu-
ga_02g00449 and TpMuguga_02g00020. All these genes
encode hypothetical proteins. Using blastx against the
NCBI non-redundant gene database reveals a conserved
Cdt1_m superfamily domain in TpMuguga_04g00278,
and a translation factor II like superfamily domain in
TpMuguga_02g00020.
Of the 61 CDSs that differed between Serengeti-
transformed and the Muguga reference, 30 also have de-
tectable differences in Kiambu5 (Additional file 2: Table
S2; Table 2). Of these, three CDSs have more than 10
non-synonymous changes relative to Muguga, namely
two of the ABC transporters (TpMuguga_01g00011 and
TpMuguga_04g00021) and one hypothetical protein
with sequence similarity to the SfiI family (TpMugu-
ga_03g00114). When compared to the Muguga reference,
the latter has only a single non-synonymous SNP in the
Serengeti-transformed stock but 21 non-synonymous poly-
morphisms in Kiambu5, while the two ABC transporters
are among the 15 genes with a large number of non-
synonymous SNPs between Serengeti-transformed and the
Muguga reference genome. The accurate number of SNPs
in many of these 61 genes could not be estimated from read
mapping between Muguga and Kiambu5 due to incomplete
read coverage over the length of each gene. The incomplete
read coverage suggests that there are additional differences
between the two isolates, and at sufficient density, to pre-
clude Kiambu5 reads to map to the sequence of their
Muguga homologs (i.e., >2 % sequence divergence), al-
though other explanations exist (see Discussion). Therefore,
these are in fact highly polymorphic genes.
Nucleotide sequence variation in known T. parva antigens
To date, fourteen T. parva genes have been identified as
antigens recognized by antibodies or T cells (Table 3).
These antigens have in some cases been demonstrated ex-
perimentally to induce an immune response in the cattle
host, but no single antigen, or evaluated combination of an-
tigens, confers immunity to both T. parva experimental
sporozoite needle infection and tick field challenge after de-
livery as recombinant subunit vaccines [24, 25]. It is, how-
ever, possible that one or more of these antigens contribute
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Table 3 List of known T. parva antigens described in literature. No variants were found for Serengeti-transformed in any of these loci, so only Kiambu5 nucleotide sequence
variants are reported
Antigen Locus Tag /2005 Locus Tag /2014 Description Protein Localization/
Confidence
Domains Kiambu5 variants Ref.
Syn Non-syn Intron
Tp2 TP01_0056 TpMuguga_01g00056 CD8+ T cell target antigen 0 / S - 2 2 [25]
gp34 TP01_0939 TpMuguga_01g00939 Hypothetical protein TP01_0939 1 / S 1 TM, 1 GPI 16 6 [47]
p32 TP01_1056 TpMuguga_01g01056 Antibody target antigen 32 kDa surface protein 0 / S 1 GPI 3 8 [25]
Tp8 TP02_0140 TpMuguga_02g00140 CD8+ T cell target cysteine proteinase 1 / _ 1 TM 0 1 [25]
X88 TP02_0148 TpMuguga_02g00148 T cell target heat shock protein 70 0 / _ - 16 0 [48]
Tp7 TP02_0244 TpMuguga_02g00244 CD8+ T cell target antigen heat shock protein 90 0 / _ - 0 0 [25]
Tp5 TP02_0767 TpMuguga_02g00767 CD8 + T cell target antigen translation initiation factor eIF-1A 0 / _ - 1 0 6 [25]
Tp9 TP02_0895 TpMuguga_02g00895 CD8+ T-cell target antigen Tp9 0 / S - ? ? [49]
Tp4 TP03_0210 TpMuguga_03g00210 CD8 + T cell target antigen T-complex protein 1 subunit eta 0 / _ - 22 1 10 [25]
p67 TP03_0287 TpMuguga_03g00287 Antibody target antigen p67 sporozoite surface protein 1 / S 1 TM, 1 GPI 0 0 [24]
Tp1 TP03_0849 TpMuguga_03g00849 CD8 + T cell target antigen apical membrane antigen 1 1 / S 1 TM 1 [25]
p150 TP03_0861 TpMuguga_03g00861 Antibody target antigen p150 microsphere protein 0 / S - 0 0 [50]
PIM TP04_0051 TpMuguga_04g00051 Antibody target antigen polymorphic immunodominant molecule (PIM protein) 3 / S 3 TM 0 0 [51]
p104 TP04_0437 TpMuguga_04g00437 Antibody target antigen 104 kDa rhoptry protein 1 / S 1 TM, 1 GPI 3 13 2 [52]
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to protective immunity when presented in the context of
challenge with the live parasite.
Interestingly, Serengeti-transformed is identical to the
Muguga reference genome in all of the currently described
antigens. Kiambu5 shows a number of variations within this
set of genes, with 65 synonymous and 31 non-synonymous
SNPs detected. In total, six of the known antigens have
non-synonymous changes, namely the CD8 T cell target
schizont antigen Tp2, Tp4, Tp8, and also gp34, p32, and
p104. In addition, three proteins, namely the p32, Tp4, and
PIM antigens all had segments with no coverage, which
precluded reliable SNP identification in these regions, and
suggested substantial differences between the two isolates.
Finally, no Kiambu5 reads mapped to the Muguga Tp9
locus, a highly variable antigen, suggesting the presence of
widespread nucleotide differences over the entirety of the
locus between these two isolates. The sequence of PIM is
known for Kiambu5, and very different to that of Serengeti-
transformed and Muguga, which are identical [26].
Most of the genes have no trans-membrane motifs
and none has more than four, which indicates that none
of these are likely to be membrane constituents. Tp4,
Tp5 and p150 all contain GPI-anchoring motifs. Most of
these are targeted to the secretory pathway with high re-
liability, confirming the widespread assumption that se-
creted proteins are likely to be targeted by the host
immune system during the schizont stage. Only half of
these genes contain non-synonymous polymorphism, a
frequency that is not significantly different from that
found for the whole genome (P = 0.2386; one-tailed Fish-
er’s exact test) and suggests that a high level of poly-
morphism is not a necessary property of antigens.
However, some of these antigens are indeed extraordin-
arily polymorphic, such as p32, p104 and gp34 with re-
spectively 8, 13 and 6 non-synonymous polymorphisms
relative to Muguga, and the Tp9 antigen apparently so
distinct that no reads map across isolates within the de-
fault read mapping stringency of BWA. This conclusion
is supported by the fact that this gene is highly poly-
morphic, with average pairwise difference between al-
leles well above 10 % (Silva, unpublished).
Identification of additional putative antigens
The interaction between antigens and the host immune
system can lead to positive selection, either due to the in-
creased fitness of non-synonymous polymorphisms or due
to frequency-dependent selection, leading to an increase in
πN and in πN/πS within genes encoding antigens relative to
other genes. Hence, signatures of positive selection are
often used to identify potential antigens [27–30]. Accord-
ingly, we searched for genes potentially evolving under
positive selection using the comparison between the
Muguga reference and Kiambu5 alleles according to three
different criteria: i) high πN, a measure of the proportion of
non-synonymous sites that differ between the alleles, (ii)
high πN/πS, a measure of the rate of amino-acid changing
mutations relative to the rate of silent mutations, and (iii) a
less well-defined criterion, namely Muguga single copy
gene for which a high proportion of the length has no
coverage from Kiambu5 reads, suggesting that the level of
sequence divergence between the two isolates is quite high,
with a resulting SNP density that prevented successful read
alignment. In the comparison between the Muguga refer-
ence and Kiambu5, πN varied between 0 – 3.29 %, with a
modal value of 0.16 % (Fig. 4a). The genes with the highest
5 % πN values, and that encode a non-hypothetical protein,
are listed in Table 4. The values of πN/πS ranged between 0
and 4.33, for genes with a valid πN/πS ratio, and the distri-
bution has a modal value of 0.11 (Fig. 4b).
The lack of read mapping across specific regions of iso-
late genomes is almost certainly a reflection of low se-
quence similarity, and hence an indicator of rapid evolution
a
b
Fig. 4 Distribution of πN and πN/πS for all genes in a comparison
between two strains of T. parva. Histograms of Histograms of (a) the
distribution of non-synonymous polymorphism (πN) and (b) the ratio
of non-synonymous to synonymous polymorphism in a comparison
between the sequence of Kiambu5 and the reference Muguga isolate.
Show are the mean, as well as the mean + 3*SD which is the cut-off
used for Additional file 5: Table S5
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rates (but see Discussion). A total of 16 Muguga genes
(corresponding to 0.39 % of all protein-coding genes)
completely lacked read coverage in Kiambu5, and 183
genes (4.48 %) had less than 10x mean coverage, pre-
venting variant calling. Of these 199 (16 + 183), 163 are
single copy genes. We identified the 100 genes with the
lowest read mapping percentage (Additional file 4:
Table S4). These include 31 novel genes, which were
absent from the original annotation of the Muguga
genome, and which are now part of the annotation be-
ing released in 2015 (http://jbrowse.igs.umaryland.edu/
t_parva/). In total, these 100 include 69 hypothetical pro-
teins, 20 genes lacking annotation, three contain conserved
DUF529 domains of unknown function, three DNA-
directed RNA polymerase subunit beta, and one of each ri-
bose 5-phosphate isomerase A (phosphoriboisomerase A),
TBC domain-containing protein kinase-like protein, DNA-
directed RNA polymerase subunit gamma, elongation
factor Tu GTP binding domain, and H/ACA ribonucleo-
protein complex subunit 3. Five of these 100 genes also had
modifications between Serengeti-transformed and Muguga,
all hypothetical proteins (Additional file 2: Table S2). One
of these (TpMuguga_04g00001) has paralogs in the gen-
ome, the remaining four being TpMuguga_01g00288,
TpMuguga_01g00464, TpMuguga_02g00526, and TpMu-
guga_02g00527, which are all close to the telomeric region
of their respective chromosomes.
Finally, we compiled a group of genes with a πN or
πN/πS value greater than three standard deviations above
the mean value of each statistic, comparable to the selec-
tion criteria used by Hayashida [10], and supplemented
with the genes selected in this study according to any of
the criteria listed above that were also detected by the
Hayashida study (Additional file 5: Table S5). The two
studies obtained slightly different distributions for πN/πS
values, which averaged 0.21 ± 0.36SD in the present
Table 4 Loci encoding well-characterized peptide products, with the highest 5 % πN value between the Kiambu5 stock and the
Muguga reference sequence. Variants in hypothetical proteins, and those not in the highest 5 % πN can be found in Additional file
3: Table S3
Locus Tag / 2005 Locus Tag IDa Product Name Domains Protein
Localization/
Confidencec
πNd πN/πSd Synd Non-synd
TP01_0066 TpMuguga_01g00066 50S ribosomal protein L33 - S/ 1 0.013 0.4313 3 3
TP01_0248 TpMuguga_01g00248 tRNAHis guanylyltransferase 1 TMb _/ 1 0.0148 0.4679 8 10
TP01_0272, TP01_0273 TpMuguga_01g00272 Kinase binding protein CGI-121 - _/ 1 0.0161 0.3261 7 8
TP01_0374 TpMuguga_01g00374 DEAD/DEAH box helicase - _/ 2 0.0131 0.3503 13 15
TP01_0405 TpMuguga_01g00405 Asparagine synthetase domain-
containing protein C4F6.11c
- _/ 1 0.0121 0.4375 14 15
TP01_1056 TpMuguga_01g01056 Merozoite Antigen 1 GPI S/ 2 0.0125 1.1773 3 8
TP01_1165 TpMuguga_01g01165 ATP-dependent RNA helicase
SUV3 homolog mitochondrial
- M/ 5 0.015 0.3049 25 23
TP01_1173, TP01_1174 TpMuguga_01g01174 Ribonuclease P protein subunit
p29
- _/ 3 0.0123 0.255 7 7
TP01_0275, TP01_0273,
TP01_0274, TP01_0272
TpMuguga_01g02345 Phosphatidylinositol 4-
phosphate 5-kinase 7
- _/ 4 0.0142 3
TP01_1063 TpMuguga_01g02455 Uncharacterized protein
C18H10.09
- _/ 1 0.0132 0.66 2 4
TP02_0369 TpMuguga_02g00369 Dual specificity protein
phosphatase 12
- _/ 2 0.0142 0.3435 11 11
TP03_0010 TpMuguga_03g00010 Archease protein family
(MTH1598/TM1083)
- _/ 1 0.0143 0.4618 6 8
TP03_0595 TpMuguga_03g00595 Ydr279p protein family (RNase
H2 complex component)
- _/ 2 0.0187 0.5673 5 13
TP03_0601 TpMuguga_03g00601 CobW/HypB/UreG nucleotide-
binding domain
- _/ 3 0.0127 0.4562 9 10
TP03_0270 TpMuguga_03g02310 Protein CyaY - _/ 5 0.0117 0.2878 36 35
TP04_0705 TpMuguga_04g00705 Maf-like protein - _/ 3 0.0115 0.5954 5 6
The previously identified antigen p32 is marked in bold
aLocus Tag Identifiers according to the updated whole genome gene structural re-annotation
bNumber of transmembrane domains
cProtein localization predictions based on TargetP: C = chloroplast; M =mitochondrion; S = Secretory pathway; _ = Any other location. Prediction confidence:
1 =max; 5 =min
dSNPs between Kiambu5 and the reference Muguga isolate
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study, compared to the study of Hayashida and col-
leagues [10] with average of 0.49 ± 0.31SD; the difference
is not surprising given that both studies are based on a
small number of parasite stocks, which differ between
the studies, and on different methodologies, both in
terms of read length, as well as stringency of read map-
ping and SNP calling. Interestingly, despite the use of
different isolates and different selection criteria, of the
262 genes prioritized by Hayashida and collaborators,
and the 175 prioritized in this study, 81 genes are
present in both sets. The 81 genes identified in both
studies include many of the known antigens, and is likely
to represent a subset of particular interest in terms of
antigenic potential (Additional file 5: Table S5).
Discussion
The importance of the Serengeti-transformed and
Kiambu5 isolates
The Muguga Cocktail vaccine is composed of three dif-
ferent isolates, each of which is thought to contribute to
the efficacy of ITM. With the goal of identifying unique
features that might be provided by each strain we se-
quenced and analyzed the components of this vaccine
cocktail. A striking result from this study is the remark-
able similarity between the Serengeti-transformed gen-
ome and that of the Muguga reference strain. When
compared to Muguga, Serengeti-transformed shows only
roughly 1.5 times the number of SNPs found in the
Muguga2 clone, which is a variant derived from the
Muguga stock. This represents 41 times fewer SNPs
than were identified between Kiambu5 and Muguga, and
almost 100 times less than the previously published
Marikebuni and Uganda stocks, when compared to T.
parva Muguga [8]. The Serengeti-transformed stock was
originally a component of a buffalo isolate that was ex-
perimentally adapted to cattle through tick passage [3].
Given the high level of sequence divergence observed
between T. parva isolates from cattle and the few avail-
able buffalo-derived isolates [10], it is very surprising
that the original Serengeti-transformed stock would be
so similar to the cattle-derived Muguga stock. Three
possible scenarios can explain this observation. It is con-
ceivable that the Serengeti-transformed stock is indeed a
buffalo isolate which is nevertheless unusually closely re-
lated to the Muguga reference isolate, making the 52 an-
notated CDS with non-synonymous SNPs between the
Serengeti-transformed and Muguga stocks extremely in-
teresting from the point of view of their potential to
confer protective efficacy. Also conceivable is the possi-
bility that the Serengeti-transformed stock was a mixed
stock containing both more “typical” buffalo-derived
strains as well as a strain similar to cattle-derived iso-
lates and very similar to Muguga, with the latter being
preferentially selected during recurrent passage. Finally,
the currently used Serengeti-transformed stock that is
contained within the Muguga Cocktail represents a his-
torical contamination with a T. parva Muguga clone.
The fact that the Serengeti-transformed strain analyzed
here shares 416 SNPs with Muguga2 (about 71 % of all
Muguga2/Muguga SNPs) indicates that the two are likely
to share a very recent common ancestor, and favors this last
scenario.
Regardless of its relationship with Muguga stock, the
Serengeti-transformed strain analyzed here is in fact the
component currently used under that name in the
Muguga Cocktail. This vaccine formulation is effective
in the field, but our observations raise the question of
whether the inclusion of this Serengeti-transformed
strain is necessary for the Muguga Cocktail to be pro-
tective, or if instead the preparation of the Muguga
Cocktail could be streamlined by eliminating this strain.
In fact, the need to re-investigate the contribution of the
Serengeti-transformed strain to the Muguga Cocktail
was first discussed as early as 2001 [4]. Interestingly,
however, despite the surprisingly high sequence similarity
between Muguga and Serengeti-transformed, there are sev-
eral proteins that differ considerably between those two
stocks. These highly variably loci include members of the
Tpr repeat family, ABC-transporters, a papain-family cyst-
eine protease, and proteins which show sequence similarity
to the SVSP and SfiI families, predicted to be involved in
parasite host interaction. Sub-telomeric gene families are
often involved in host-pathogen interactions, making these
genes of particular interest.
Finally, whether or not the re-introduction of a more
divergent, buffalo-derived T. parva stock could improve
further the protective performance of the Muguga Cock-
tail under different field conditions will require further
studies. One possible constraint is the difficulty to
propagate buffalo-derived strains in ticks and cattle to
generate sufficient quantities for stabilate production.
Incomplete coverage with mapped reads can result
from several factors including (i) heterogeneity in clon-
ing and/or sequencing efficiency of different genomic re-
gions (say, those differing in GC content), (ii) the fact
that whole genome shotgun sequencing coverage follows
a Poisson distribution, with some regions, by chance, be-
ing sequenced at much lower level that others, and
resulting in some regions with no coverage at all in most
genomes sequenced to a reasonable depth of coverage,
(iii) ambiguity in mapping location (e.g., reads that
match equally well to multiple locations in the genome)
or (iv) high degree of sequence divergence between se-
quence reads and the target genome. The difference in
coverage between Muguga2 and Serengeti-transformed
likely results from the difference in data volume (Additional
file 1: Table S1) coupled with the random distribution of
reads described in (ii) above. The fact that many of the
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genes with incomplete or no read coverage in the compari-
son between Muguga and Kiambu5 are known to be of
average GC content and high polymorphism suggest
that, for the most part, factor (iv) above is the main
reason for the incomplete read coverage observed for
Kiambu5. The comparison between Muguga and Kiambu5
clearly highlights the limitations of read mapping-based
characterization of gene evolution rates. In particular, the
precise quantification of genetic differences between diver-
gent isolates is restricted to genes with low polymorphism.
Reliable estimates of sequence polymorphism for rapidly
evolving genes, and in-depth characterization of the select-
ive pressures governing their evolution, will require de novo
genome assemblies from which complete gene sequences
can be extracted and analyzed.
Implications of the sequence data for ITM vaccine quality
control
Previous studies of the genetic composition of stocks
and stabilates comprising the Muguga Cocktail utilized
Southern blotting with multicopy probes [4], nucleotide
sequencing and a panel of mini- and micro-satellite
markers [31]. Application of these approaches [4, 26, 32]
also revealed close similarity between Muguga and
Serengeti-transformed including the sequence of the
gene encoding the polymorphic immunodominant mol-
ecule (PIM). These two studies [26, 32] additionally re-
vealed diversity within DNA prepared directly from the
sporozoite stabilates. A more recent study using only
five satellite markers [33], revealed even more hetero-
geneity within the DNA of Muguga and Serengeti-
transformed stabilates, while Kiambu5 appeared to be
clonal with these markers. The stocks that were used for
infection of animals were not cloned, and these stabilate
genotyping studies do, in fact, suggest that multiple
clones could have been present in the initial sporozoite
inoculum [32]. However, our analyses reveal the pres-
ence of a single genotype in both the Serengeti-
transformed and Kiambu5 DNA samples. Taken together
these observations suggest that, upon infection, only one
of possibly multiple clones present will expand to be-
come the predominant and only detectable parasite in
the infection. The phenomenon of selective amplification
of a predominant clonotype on passage through cattle
and ticks has been observed previously. For example,
when the Marikebuni stock was used to infect cattle, 48
clonal genotypes were reduced to 18 in a single passage,
and 75 % of these were derived from one highly inbred
genotype [34]. The study by Patel and collaborators [33]
did not reveal the very extensive genetic divergence
between Serengeti-transformed/Muguga and Kiambu5,
perhaps because of the markers used, which were se-
lected from a pool of 31 VNTR (variable number of tan-
dem repeat) markers that were strongly biased towards
those that detect diversity within the T. parva Muguga
stock. The higher information content and value of
SNP-based, genome-wide genotyping is clearly illus-
trated by the discrimination of Muguga and Serengeti-
transformed at specific loci, particularly in the ATP
binding cassette transporter family, despite their overall
similarity.
The sub-telomeric SVSP gene family members are
predicted to be part of the schizont secretome of T.
annulata and T. parva that has expanded selectively
when compared to the non-transforming T. orientalis
genome [10]. Sequences of SVSP gene family members
differ between all isolates compared here, giving each
isolate a unique SVSP genomic signature. Investigation
of cellular immune responses in ITM-vaccinated cattle
using peripheral blood mononuclear cells stimulated
by sets of overlapping synthetic peptides covering
these variant SVSP is well justified based on the data
presented in this study.
The close dependency on the Muguga reference gen-
ome poses significant challenges to the identification of
novel features in each of the components of the Muguga
Cocktail. As discussed above in terms of read mapping,
genetic differences between the isolates can only be
identified if they are sparsely distributed and located
close to conserved regions that can anchor the mapped
reads. In addition, the only genes analyzed were those
present in the reference Muguga isolate, and so there
are currently no features known to be unique to the
Kiambu5 or Serengeti-transformed genomes, such as the
presence of previously unknown genes or genomic rear-
rangements. While the IonTorrent 316 sequencing chip
produced good quality data, it did not allow the generation
of a high quality de novo genome assembly. Further sequen-
cing using paired-end or long-read data will be needed to
identify genomic rearrangements, sequences that are
unique to specific stocks, and perform analyses of the full
complement of rapidly evolving genes.
Relevance to development of other whole-organism
vaccines
Recently, there has been renewed enthusiasm for the
prospect of the development of a effective whole live
Plasmodium falciparum sporozoite vaccine, based on
the encouraging outcome of a number of phase I clinical
trials [35]. The possibility of manufacturing cryopre-
served, metabolically active, live P. falciparum sporozo-
ites (PfSPZ) suitable for clinical application has been a
milestone for this vaccine development approach [36].
The T. parva Muguga Cocktail is composed of three
isolates, two of which are nearly identical, and which
together represent most likely only a small amount of
the genetic variation circulating in the field (Fig. 2).
The fact that this preparation is able to confer high
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levels of protection against highly diverse T. parva
cattle-transmissible field isolates, and that population
variation in P. falciparum is much lower than that is
observed in T. parva [10, 37], is highly supportive of a
similar initiative in malaria.
Conclusions
We sequenced the whole genomes of three T. parva
component stocks (Muguga Cocktail) that form the basis
of the ITM procedure for control of East Coast fever in
cattle in East Africa. The Serengeti-transformed isolate
currently used in this cocktail, even though originally
isolated from the main wildlife host, African Cape buf-
falo (Syncerus caffer), is very similar to the cattle-derived
stock from which the T. parva Muguga reference isolate
was cloned. All non-synonymous SNPs were found in
only 53 genes, mostly sub-telomeric loci and/or genes
predicted to encode antigenic proteins. The Kiambu5
stock is much more divergent, containing approximately
40,000 single nucleotide differences relative to Muguga,
including >8,500 amino acid-changing mutations that
affect 42.5 % of the predicted proteins. Importantly, the
genetic content and variation of Kiambu5, Muguga and
Serengeti-transformed represent only a small proportion
of the genetic variation of cattle-derived T. parva iso-
lates circulating in the field. Our results demonstrate
that whole organism-based, live vaccines against highly
polymorphic apicomplexan parasites can be highly ef-
fective. The Muguga cocktail does not, however, cross-
protect against all buffalo-derived T. parva in Eastern
Africa [38]. Genome-wide studies that focus on genetic
differences between cattle- and buffalo-derived T. parva
parasites will shed light on the genomic basis of vaccine
evasion by the latter, and inform the design of more
broadly protective vaccine preparations.
Methods
Biological samples
The three T. parva stocks that comprise the Muguga
Cocktail version of ITM are compared in this study:
Muguga, Kiambu5, and Serengeti-transformed. The
origin of these stocks is as follows:
i. Muguga: the reference T. parva genome sequence
[19] was derived from piroplasms, which were
purified following infection of several cattle with the
cloned parasite stabilate 3308 [39]. The T. parva
Muguga clone 2 sequence was derived from
piroplasms isolated from animal BM256 infected
with a second Muguga cloned stabilate, 3968, that
differs from the reference Muguga isolate in the
organization of the hyper-variable Tpr locus,
according to Southern blot data (R. Bishop,
unpublished data).
ii. The Kiambu5 genome sequence was produced from
purified piroplasm DNA generated from reference
stabilate 4137, which itself is directly derived from
the seed stabilate KV 68 that was used to produce
the first bulk stabilate of the Muguga Cocktail
vaccine, FAO1, by infection of animals and
application of ticks [7].
iii. The Serengeti-transformed genome was produced from
purified piroplasm DNA from an animal infected with
the seed stabilate Serengeti-transformed 69 which
represented the direct precursor present in the FAO1
ITM vaccine stabilate. The Serengeti-transformed stock
was originally established from a buffalo isolate that
was experimentally adapted to cattle through extensive
tick passage [3].
Ethics statement
The ILRI’s Institutional Animal Care and Use Committee
(IACUC) was established in 1993 to ensure that inter-
national standards for animal care and use are followed in
all ILRI research involving use of animals. ILRI has
complied voluntarily with the UK's Animals (Scientific Pro-
cedures) Act 1986 (http://www.homeoffice.gov.uk/science-
research/animal-research/) that contains guidelines and
codes of practice for the housing and care of animals used
in scientific procedures. The study reported here was car-
ried out in strict accordance with the recommendations in
the standard operating procedures of the ILRI IACUC and
adequate consideration of the 3R's (Replacement of animal
with non-animal techniques, Reduction in the number
of animals used, and Refinement of techniques and
procedures that reduce pain and distress). Generation
of piroplasms for this work was done under IACUC-
approved protocol with ILRI reference number 2011-07.
Experimental infection of cattle, piroplasm purification
and DNA extraction
For generation of piroplasms from Kiambu5, experi-
ments were conducted using four Friesian calves each
aged six months. Prior to infection, the cattle were
screened using an indirect ELISA based on the recom-
binant PIM antigen and with a T. parva-specific p104
PCR assay to confirm that there was no prior exposure
to T. parva. Each calf was infected with a standard dose
(1:20 dilution) of a T. parva Kiambu5 reference stabilate
derived from the Malawi 68 (KV68) vaccine seed stabi-
late. The diluted stabilate was inoculated subcutaneously
below and in front of the left parotid lymph node. The
animals were treated daily with a low dose (10 mg/kg) of
oxytetracycline from day 10 post-infection. This proced-
ure ensured that the clinical distress on the animal was
reduced and also protected the animals against prema-
ture death prior to the development of piroplasm para-
sitaemia, which ranged between the relatively low levels
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of 0.98 and 1.62 %. During the course of infection, the
animals were monitored for development of fever and
presence of schizonts in blood and lymph node smears.
Clinical reactions were recorded on standard ILRI ani-
mal record experimental data recording forms. Due to
the typically low levels of piroplasm parasitaemia ob-
served in cattle infected with T. parva Kiambu stocks, it
was necessary that a large volume of blood be collected
from all infected animals to purify sufficient amounts of
piroplasms for DNA extraction. Exsanguination under
general anesthesia was performed by carotid artery can-
nulation after the animals had developed a minimum
piroplasm parasitaemia of 2 %. Venous blood was col-
lected in Alsevers solution containing heparin at a con-
centration of 50 i.u/ml of blood and then centrifuged at
3500 rpm for 30 min to remove the serum and buffy
coat layer. The cells were washed three times by re-
suspending in fresh cold Alsevers solution and centri-
fuged at 3500 rpm for 30 min. Finally, the washed red
blood cells were lysed in pre-warmed 1 mg/ml saponin
at 37 °C for 30 min, then washed with Alsevers solution
and centrifuged as before. The supernatant was collected
using a trap bottle and centrifuged at 10,000 rpm for
30 min, then carefully discarded while retaining the piro-
plasm pellet, which was then washed three times in
Alsevers and finally re-suspended in TEN- buffer (10 mM
Tris-Cl;1 mM EDTA; 100 mM NaCl, pH 8.0). The purified
piroplasms were then stored at -20 °C. Procedures for ani-
mal infection and purification of piroplasms from T. parva
Serengeti-transformed and Muguga2 were similar, except
that the administration of oxytetracycline was not used to
prolong infection. Piroplasm samples for these two isolates
were generated in or before 1999, in the context of previous
studies [19], but the genome was not sequenced. Genomic
DNA was subsequently prepared using standard phenol/
chloroform and ethanol precipitation extraction procedure
as described elsewhere [8].
Genome sequencing strategy, read mapping, and variant
calling
The Muguga2 DNA sample was sequenced at the Func-
tional Genomics Centre Zurich, Switzerland, using a
Roche 454 GS FLX sequencing platform with Titanium
chemistry. A shotgun library and an 8 Kb mate-paired li-
brary were prepared and sequenced according to the
manufacturer’s protocols. The Serengeti-transformed
DNA sample was sequenced at ILRI using a similar se-
quencing strategy, except that the mate-paired library
was prepared with 3 Kb inserts. Theileria parva stock
Kiambu5 was sequenced at the Swedish National Genomics
Infrastructure, in Uppsala, Sweden. Two samples, contain-
ing a total 2.2 μg genomic DNA were sheared to a target
size of 300 bp, followed by two cycles of amplification. The
samples were then pooled and the library finalized using
the Ion OneTouch system with the Ion PGM template OT
300b kit. The library was sequenced on a 316 chip using
the Ion PGM™ Sequencing 300 Kit on the Ion PGM™ sys-
tem. The sequence data have been deposited with GenBank
Short Read Archive database under BioProject accession
number PRJNA276471.
The Kiambu5 reads were aligned against the Muguga
reference strain (Genbank accession numbers: AAGK0100
0001- AAGK01000009) [19], using the Burrows Wheeler
aligner (BWA) [40] with default parameters. Reads with a
negative mapping score were removed. The Serengeti-
transformed and Muguga2 reads were aligned with the GS
Reference Mapper (454 Life Science), using the same
Muguga reference strain. For each of the three isolates’
read dataset, the number of base pairs in the Muguga ref-
erence genome with no read coverage determined from
the bam files, using a custom script.
Indels and SNPs for all isolates were identified using the
Genome Analysis Toolkit (GATK) from the Broad Institute
[41], and SNPs were filtered using SAMtools [42] according
to the following filter: (DP < 12) || (QUAL < 50) || (SB > -
0.10) || (MQ0 > =2 && (MQ0/(1.0*DP)) > 0.1), where DP is
total read coverage depth, QUAL is quality, SB is strand
bias, and MQ0 is the number of reads with mapping quality
zero. SNPs were classified into synonymous, non-
synonymous, nonsense, intronic, and indels based on
the updated gene structural annotation of the entire
reference T. parva Muguga genome assembly (http://
jbrowse.igs.umaryland.edu/t_parva/; Silva, in prepar-
ation), using VCF_annotator (http://sourceforge.net/
projects/vcfannotator/) and in-house python scripts
towards the Muguga reference (GenBank accession
numbers: AAGK01000001- AAGK01000009) [19]. The
locus tag identifiers for the new annotation are very similar
to those in the original annotation for genes with no or
minor structural changes, such as the addition of UTRs or
alterations of intron-exon boundaries (e.g., TP01_0056 sim-
ply becomes TpMuguga_01g00056). However, in the case
of genes with a fundamentally difference structure, such as
new genes, genes that have been split to result in two or
more genes in the current annotation, or cases in which
two or more original genes have been merged, then the
gene numbering will be altered to start in the 2000’s (e.g.,
TpMuguga_01g02345 is located in chromosome 1, and has
gene number 2345).
Gene functional characterization and gene family
identification
Additional information for loci of interest was obtained
from publicly available sources. Transmembrane motifs
were identified with TMHMM2.0 [23], and GPI-anchored
motifs with GPI-SOM [43]. For selected genes for which
the product was annotated as “hypothetical proteins” with
our stringent functional assignment pipeline, we performed
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additional sequence similarity searches against the public
databases GenBank (non-redundant proteins), SwissProt,
and KEGG to determine if they belong to known protein
families or contain known functional motifs.
In order to estimate the number and composition of mul-
tigene families in the T. parva genome, all genes were com-
pared to the complete set of T. parva genes from the
reference annotation using BLAST [44]. A gene was con-
sidered to have paralogs if it had at least one blastn hit with
an expectation value ≤ 1e-3, covering at least 50 % of either
the query gene or the target gene.
Molecular evolution
In order to identify genes that encode rapidly evolving
genes, and in particular those that may be evolving
under positive selection, the variants identified in the
Kiambu5 strain relative to the reference genome were
used to generate Kiambu5 “pseudo-sequences”. These
sequences correspond to the homologous sequence from
the T. parva Muguga reference with the exception of the
positions in which SNPs were identified. These “pseudo-
sequences” are potentially conservative in their differ-
ence to the T. parva Muguga homologs, due to mapping
stringency limitations and variant filtering. All coding se-
quences (CDSs) from the Muguga reference genome
were aligned to the inferred Kiambu5 CDSs obtained
from the pseudo-sequences, and πN/πS ratios were cal-
culated with the LPB93 algorithm of the yn00 program,
as implemented in the PAML package [45], where πN
and πS are, respectively, the rate of non-synonymous
and of synonymous polymorphisms per site. All CDSs
with an πN > 0 were identified. The value of πN/πS was
estimated for those genes for which the statistic is valid
(i.e., those for which πS > 0).
Genetic relationship between isolates
The relationship and relative genetic distances between
isolates were visualized with a dendrogram created using
the nucleotide sequences of 200 protein-coding genes,
selected pseudo randomly using the Python2.7 random
library (seed 1). The sequence of the selected genes in
each isolate was inferred from the SNP calls, with
“pseudo-sequences” generated as described above, and
all genes were concatenated, creating pseudo-contigs.
The pseudo-contigs were modified using a series of at
least 20 N’s to separate genes and prevent frame-shifts.
These pseudo-contigs were then aligned using clustalw2
[46], and a maximum-likelihood phylogeny was calcu-
lated with MEGA6, using default parameters which in-
cluded the Tamura and Nei model of evolution. Clade
support was estimated from 500 bootstrap replicates.
The branch lengths in the dendrogram are only an ap-
proximation of the true genetic distance between isolates
for several reasons, including that (i) the subset of ~5 %
of all genes used to calculate the relationships may not
be representative of the whole genome, (ii) gene se-
quences were inferred from SNPs identified through
read mapping against the reference rather than from de
novo genome assemblies, and (iii) since T. parva under-
goes recombination, a bifurcating tree is most likely not
a strictly correct depiction of the relationship between
these genome sequences.
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